A Single Ascending and Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3873862 in Healthy Participants
Latest Information Update: 20 May 2025
At a glance
- Drugs LY 3873862 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
Most Recent Events
- 11 May 2025 Status changed from active, no longer recruiting to completed.
- 06 Apr 2025 Status changed from recruiting to active, no longer recruiting.
- 05 Jun 2024 Number of treatment arms increased from 4 to 6 by the addition of Experimental and Placebo Comparator arms for Part C.